Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer

Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in initial trials. This article reviews the preclinical evidenc...

Descripción completa

Detalles Bibliográficos
Autor principal: Harvey, R D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685326/
https://www.ncbi.nlm.nih.gov/pubmed/24690569
http://dx.doi.org/10.1038/clpt.2014.74

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685326/
https://www.ncbi.nlm.nih.gov/pubmed/24690569
http://dx.doi.org/10.1038/clpt.2014.74

Ejemplares similares